The US Food and Drug Administration (FDA) has approved the mNEXSPIKE vaccine, developed by Moderna, for people at high risk of severe COVID-19 disease. This approval comes after a Phase 3 trial showed improved efficacy in both those under 65 and those over 65 compared to Moderna’s original vaccine Spikevax. The new vaccine aims to protect vulnerable populations from the ongoing public health threat posed by COVID-19, with Moderna expecting it to be available for the upcoming respiratory virus season.
Source: https://www.axios.com/2025/05/31/fda-approves-moderna-mnexspike-covid-19-vaccine